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Abstract
Background: Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently
insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy.
Methods and Findings: 14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eight week cycle
of intravenous ascorbic acid (three infusions per week), using a dose escalation design, along with standard treatment of
gemcitabine and erlotinib. Of 14 recruited subjects enrolled, nine completed the study (three in each dosage tier). There
were fifteen non-serious adverse events and eight serious adverse events, all likely related to progression of disease or
treatment with gemcitabine or erlotinib. Applying RECIST 1.0 criteria, seven of the nine subjects had stable disease while the
other two had progressive disease.
Conclusions: These initial safety data do not reveal increased toxicity with the addition of ascorbic acid to gemcitabine and
erlotinib in pancreatic cancer patients. This, combined with the observed response to treatment, suggests the need for a
phase II study of longer duration.
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Introduction
Pancreatic cancer survival continues to be amongst the shortest
of all cancers, and new therapies are urgently needed. The
majority of patients with pancreatic cancer already have metastatic
disease at clinical presentation [1], and many patients progress
quickly even with standard treatment of gemcitabine alone or
gemcitabine plus erlotinib [2,3,4].
Ascorbic acid (ascorbate, vitamin C) in cancer care has had a
labyrinthine history [5]. Several decades ago, observational and
anecdotal clinical data obtained by Cameron and Pauling
suggested an unexpected increase in survival in some patients
who received 10 grams of ascorbic acid daily compared to
retrospective controls [6,7]. However, two double-blinded place-
bo-controlled trials showed no efficacy of the same ascorbic acid
dose [8,9], and thus, ascorbate was dismissed from therapeutic
consideration in 1985 [10]. A more recent review and analysis of
patients receiving oral doses of ascorbic acid demonstrated no
benefit in cancer patients [11].
Since then, renewed interest in ascorbic acid and cancer
treatment arose serendipitously from clinical pharmacokinetics
studies of ascorbic acid in healthy adults [12,13]. In those studies,
to determine true bioavailability, subjects received both oral and
intravenous ascorbate. When ascorbic acid was given intrave-
nously in doses above 0.5 grams, it was found that the usual tight
control of ascorbic acid concentrations with oral doses was
bypassed. Only intravenous administration resulted in very high
ascorbic acid concentrations until renal excretion restored
homeostasis. With these pharmacokinetics data as background,
investigators revisited the earlier work on cancer and found that in
the studies by Cameron and Pauling, patients received both
intravenous as well as oral ascorbate, while patients from the later
studies received only oral doses.
Detailed pharmacokinetics studies in humans and animals have
confirmed that intravenous ascorbate in pharmacologic doses can
produce peak plasma concentrations that are several hundred fold
higher than those possible from maximal oral doses [12,13]. In cell
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ascorbate kill a number of cancer cell types, but not normal cells,
and decrease tumor growth in mice [14,15]. In humans, plasma
ascorbate concentrations produced by intake of vitamin C rich
foods (fruits and vegetables) are usually ,0.1 mM, and by higher
intake from supplements are ,0.15 mM [13,16,17]. In rodents,
baseline plasma ascorbate concentrations are approximately
0.05 mM. When parenteral pharmacologic ascorbate doses are
administered to animals or humans, peak plasma concentrations
are as high as 30 mM [15,18]. Across this broad range of
concentrations, ascorbate in plasma readily diffuses into extracel-
lular fluid [15,19]. At extracellular fluid ascorbate concentrations
above 3–4 mM, hydrogen peroxide concentrations above 5 mM
are detectable in this fluid but not in blood [14,15,19]. Such
hydrogen peroxide concentrations do not otherwise occur with
physiologic ascorbate concentrations. Hydrogen peroxide plus
ascorbate in extracellular fluid results in formation of reactive
oxygen species, which are selectively toxic to cancer cells but not
normal tissues [14,15]. Thus, pharmacologic ascorbate is a pro-
drug for production of sustained concentrations of hydrogen
peroxide in extracellular fluid but not blood [14,15,19].
There are limited human data on the use of pharmacologic
ascorbate, despite surprisingly current wide use by practitioners of
complementary and alternative medicine [5]. One clinical safety
study of pharmacologic ascorbate in patients with a variety of
advanced cancers did not reveal untoward effects [18].
Pancreatic cancer is sensitive to pharmacologic ascorbate both
in vitro and in animal models [15]. Emerging evidence in both
model systems indicates that ascorbate has synergistic effects with
gemcitabine [20]. When pharmacologic ascorbate was combined
with gemcitabine, synergy was observed in all eight cell lines tested
in vitro. In mouse models, ascorbate- gemcitabine combinations
were more effective at inhibiting tumor growth compared to
gemcitabine alone and also produced gemictabine dose-sparing
effects.
Given what is known about the relative safety of pharmacologic
ascorbate and its potential for efficacy, coupled to the pressing
need for new treatments, we conducted a phase I trial of
intravenous ascorbate added to gemcitabine and erlotinib in
patients with stage IV metastatic pancreatic ductal adenocarcino-
ma with the specific primary aim of assessing safety and the
secondary aim of assessing response to treatment. We investigated
adverse events, measured peak plasma ascorbic acid concentra-
tions after infusions, and conducted imaging pre- and post-
treatment.
Methods
Ethics Statements
This research was approved by the Thomas Jefferson University
Institutional Review Board. Written informed consent, approved
by the Thomas Jefferson University Institutional Review Board,
was received from all patients who participated in the study.
Clinical Investigation was conducted according to the principles
expressed in the Declaration of Helsinki.
Study design
This was a phase I study of patients with histologically or
cytologically confirmed metastatic stage IV pancreatic ductal
adenocarcinoma, conducted at the Thomas Jefferson University
and Hospital between July, 2009 and July, 2011. The study was an
open-label, dose-escalating trial that utilized a 3+3+3 design (see
Figure 1 for CONSORT diagram [21]). The protocol for the
study and supporting CONSORT checklist are available as
supporting information; see Protocol S1 and Checklist S1. Patients
were referred by the study oncologists who were aware of the study
inclusion/exclusion criteria. All referred patients are included in
the data presented. However, it is possible that some patients who
met study criteria were referred to another competing trial.
Recruitment occurred July 2009 to July 2011.The first cohort
received 50 grams intravenous ascorbate per infusion, the second
cohort received 75 g/infusion, and the third cohort received
100 g/infusion. A cycle consisted of three infusions per week
performed on separate days, for 8 weeks (maximum twenty-four
infusions total per dose level). One hundred grams per infusion
was the target ceiling dose for this study, because this dosage was
estimated to produce a blood level high enough to achieve the
proposed mechanism of action of elaborating hydrogen peroxide
[22]. Fifty grams was chosen as the starting dosage based upon
available safety data [5,20]. Ascorbate blood levels were drawn
immediately after the first target dose was reached and again at the
final dose of the cycle for the patients in the 75 g and 100 g dosage
tiers.
The following inclusion and exclusion criteria were used for
subject recruitment into the study. Patients had newly diagnosed,
stage IV pancreatic ductal adenocarcinoma, were not eligible for
surgical resection, and had not yet been treated. The diagnosis was
established by histology or cytology. Patients had an Eastern
Cooperative Oncology Group (ECOG) Performance Status of 0–
2. Laboratory requirements were an absolute neutrophil count
$1,500/mm3, hemoglobin .8 g/dL, platelet $100,000/mm3,
total bilirubin #1.5 mg/dL, creatinine #2.0 mg/dL, transami-
nases #2.56 upper limit, urine uric acid ,1,000 mg/d, urine
pH,6, and urine oxalate ,60 mg/d. Patients were excluded if
they had documented glucose-6-phosphate-dehydrogenase
(G6PD) deficiency or a history of oxalate renal calculi, since high
levels of ascorbic acid are known to cause hemolysis in G6PD
deficient individuals and kidney stones in those patients with a
preexisting risk for oxalate stones. Patients were excluded if they
were currently receiving chemotherapy or radiation therapy or
enrolled in other trials currently or in the preceding 1 month.
Patients with co-morbid condition that would affect survival such
as end stage congestive heart failure, unstable angina, myocardial
infarction within 6 weeks of study, or chronic active hepatitis or
cirrhosis also were excluded.
All subjects meeting eligibility criteria were enrolled to receive
gemcitabine, erlotinib, and intravenous ascorbate as first line
treatment. Gemcitabine was administered intravenously at a dose
of 1000 mg/m
2 over 30 minutes, on day 1, once weekly for 7
weeks followed by a 1 week rest. Erlotinib was given orally in a
single daily dose of 100 mg per day for eight weeks.
Data were obtained regarding laboratory values and adverse
events throughout the treatment period. Ascorbic acid concentra-
tions in the serum were measured by HPLC with coulometric
electrochemical detection [13]. Monitoring and adverse events
were evaluated by standard National Cancer Institute (NCI)
clinical criteria 3.0 [23]. At the beginning and end of the ascorbate
treatment cycle, subjects were evaluated by x-ray computed
tomography (CT) imaging of the chest, abdomen, and pelvis, for
possible response to treatment based upon Response Evaluation
Criteria In Solid Tumors (RECIST 1.0) criteria [24]. The expert
radiologist who evaluated CT images was blinded to patient
treatment.
Ascorbic Acid Preparation
Ascorbic Acid Injection USP was supplied by Bioniche Pharma
(Rosemont IL) as sterile solution of ascorbic acid in water for
parenteral use. The product was supplied in sterile 50 mL single
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(2.84 mmol), edetate disodium 0.025%, and water for injection
with pH (range 5.5 to 7.0) adjusted with sodium bicarbonate,
hence providing ,2.84 mmol sodium and an osmolality of
2.84+2.84=5.7 mOsm/mL.
Results
Patient Cohort
To meet the goal of 9 patients completing the trial, 14 patients
were recruited from July, 2009 to July, 2011: 4 males and 10
females, mean age of 64.4610.0 (range 47–81)(Table 1). All
patients had stage IV pancreatic ductal adenocarcinoma. Nine
patients (three in each dosage tier) received the full cycle of
ascorbic acid plus gemcitabine and erlotinib, with full cycle
defined as at least 2466 ascorbic acid treatments for 861 weeks.
These nine subjects were evaluated by CT imaging pre and post
therapy. Five of the fourteen enrolled patients did not complete the
study and therefore were not evaluable by CT imaging. Of these,
two subjects (003 and 007) chose not to continue because it was
too difficult to come in for the treatments, and three subjects died
from rapid disease progression: subject 009 after 5 weeks of
treatment; subject 011 after 3 weeks of treatment, and subject 013
after 1 week of treatment.
Safety and Adverse Events
When patients received intravenous ascorbic acid, they
frequently reported mild lightheadedness or nausea which was
expected from the osmotic load and resolved with eating and
drinking. Overall, for the total cohort of 14 patients, there were 23
Figure 1. Study CONSORT flow diagram.
doi:10.1371/journal.pone.0029794.g001
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adverse events are shown in Table 2. All of these adverse events
were most likely attributable to progression of disease or
concomitant treatment with gemcitabine and/or erlotinib. Re-
garding the serious adverse events: one male subject was
hospitalized with low hemoglobin due to an internal bleed and
then was subsequently placed on hospice care. Two subjects were
found to have a pulmonary embolism most likely related to the
underlying pancreatic cancer that has a reported rate of
pulmonary embolism between 20–50% [25]. Three subjects died
from progression of the underlying cancer, as determined clinically
and with confirmation by the data safety and monitoring board.
One patient was hospitalized twice, once for anemia symptoms
and once for a urinary tract infection which both resolved. A male
subject was hospitalized with abdominal pain and ileus which in
retrospect were present at study onset, and he received total
parenteral nutrition and nasogastric tube feeds, but was finally put
on hospice care before dying of the underlying cancer. None of
these subjects received the full treatment with intravenous ascorbic
acid. None of these adverse events appeared to be specifically
related to the ascorbic acid treatment since each of these events is
frequently observed in the normal progression of pancreatic
cancer patients and/or gemcitabine and erlotinib treatment.
Pharmacology
Ascorbic acid concentrations were measured immediately after
infusion end in the six patients receiving the two upper dosage tiers
of either 75 g or 100 g per infusion (see Figure 2). Millimolar
concentrations were achieved as expected, particularly among
those receiving 100 g per infusion. For these patients the plasma
ascorbate level was between 25.3 and 31.9 millimoles/L. They
had no increase in adverse events compared to the other dosage
tiers or to what would be expected from gemcitabine and erlotinib
alone or from progression of disease.
Response to Treatment
To assess treatment response by imaging, all nine patients who
completed the protocol underwent pre- and post-treatment CT
scans or PET-CT scans. Scans were evaluated, by an expert
radiologist blinded to the clinical conditions of the patients, for
the change in size of the primary tumor (Figure 3) as well as by
RECIST 1.0 criteria (Table 3). As shown in Figure 3, eight of
nine patients had a reduction in size of the primary tumor (with
one patient having no change in size). By RECIST 1.0 criteria, 7
patients had stable disease and 2 patients had progressive disease
(non-responders). In addition, 3 patients did not have post
imaging results because they died before the end of the treatment
period. With these patients included, the total for progressive
disease (non-responders) is 5 patients. There were no distinguish-
ing characteristics regarding the patients who died during the
study compared to those who completed the study. Finally,
although our analyses were focused on the eight week treatment
period, we obtained additional data for preliminary survival
assessments. The estimated mean progression free survival
measured from the first day of treatment until evidence of
progression was 89 days (SD 77 days) and the overall survival was
182 days (SD 155 days).
Table 1. Patient demographics and disease status.
ID
Age/
Gender Time Dx to Rx ECOG Status
Dx (in addition to pancreatic
primary mass)*
Dose Level (g/
infusion) Doses Weeks
Weight
Pre Rx
(lbs)
Weight
Post Rx**
(lbs)
001 60 M 3 wks 0 Liver/lung/media 50 24 8 143 134
002 75 F 5 wks 2 Liver/retroper 50 24 8 143 134
003 81 F 5 wks 1 Locally adv/liver 50 3 1 100 ----
004 64 F 4 wks 1 Liver 50 18 7 157 148
005 69 M 6 mon 1 Abdomen 75 23 8 167 157
006 66 F 2 wks 0 Media/retroper 75 22 8 224 202
007 47 F 6 wks 0 Liver/peritoneal 75 3 1 100 ----
008 75 F 3 wks 1 Liver 75 21 7 156 144
009 51 M 3 mon 1 Liver/peritoneal 75 14 5* 162 168
010 48 F 3 wks 1 Liver 100 21 8 186 169
011 67 F 4 wks 1 Liver/peritoneal 100 9 3* 140 144
012 67 F 4 mon 1 Locally adv/bone 100 24 8 147 133
013 65 M 4 mon 2 Liver/peritoneal 100 3 1* 137 ----
014 66 F 3 wks 1 Liver 100 24 8 148 141
Bone=bone metastases.
Liver=liver metastases.
Locally adv=locally advanced spread of cancer.
Abdomen=Metastases within the abdomen distant from the pancreas.
Lung=lung metastases.
Media=mediastinal metastases.
Peritoneal=peritoneal metastases.
Retroper=retroperitoneal nodes or metastases.
*Patient died during study.
**Weights were obtained on the first and last day of the ascorbic acid infusions.
doi:10.1371/journal.pone.0029794.t001
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The goals of this phase I trial were to provide an initial safety
evaluation of ascorbic acid added to gemcitabine and erlotinib in
patients with stage IV pancreatic cancer, to measure whether
predicted ascorbic acid concentrations could be achieved, and to
preliminarily assess any response to treatment. In the nine patients
who completed the study, ascorbic acid concentrations were
reached safely and with minimal associated adverse events that
could be attributed to ascorbic acid. Overall, the safety data do not
reveal adverse events other than what might be expected for
progression of pancreatic cancer and/or treatment with gemcita-
bine and erlotinib. Deaths of three patients who died before
completing the study were attributable to underlying and rapidly
advancing disease, as affirmed by the Data Safety and Monitoring
Board.
Peak ascorbic acid concentrations were achieved as high as 30
millimoles/L in the highest dose group. These concentrations are
similar to reported concentrations in patients who received
ascorbic acid intravenously without concomitant chemotherapy
[20]. For a frame of reference, the usual plasma ascorbic acid
concentrations in people are 0.010–0.080 millimoles/L and are
dependent on dietary and supplement intake. Even with massive
oral supplementation of many grams daily taken every few hours,
Table 2. Adverse Event Chart for all 14 patients (based on
standard NCI criteria).
Adverse Event Number of Events
Low Platelets
Grade 1 6
Grade 2 2
Low Hemoglobin
Grade 2 1
Grade 3 2
Low Absolute Neutrophil Count
Grade 3 1
Elevated Glucose
Grade 2 1
Gastrointestinal
Ileus (Grade 3) 1
Discomfort (Grade 2) 1
Ascites (Grade 2) 1
Infection
Conjunctival (Grade 2) 1
Urinary Tract Infection (Grade 3) 1
Pulmonary Emboli
Grade 4 2
Death
Grade 5 3
doi:10.1371/journal.pone.0029794.t002
Figure 2. Peak plasma ascorbic acid concentrations in millimoles/L after the initial dose and final dose (measurements after the
final dose were unavailable for patients 008 and 014). The green line represents the highest plasma concentration expected with maximally
tolerated oral doses of ascorbic acid [13].
doi:10.1371/journal.pone.0029794.g002
Figure 3. Tumor size initially and after 8 weeks of treatment
with ascorbic acid, gemcitabine, and erlotinib for each of the
patients who completed the study.
doi:10.1371/journal.pone.0029794.g003
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millimoles/L [13]. The data from this trial indicate that
pharmacologic ascorbic acid concentrations were achievable in
patients who received intravenous ascorbic acid in combination
with gemcitabine and erlotinib.
CT images at the beginning and end of 8 weeks of treatment
revealed that primary tumor size (target lesion) decreased in 8 of 9
subjects; was stable in the one subject who did not have a decrease;
and specifically decreased in the three subjects who received the
highest ascorbic acid dose (see Table 3 and Figure 3). Clinically,
these findings are not typical with treatment using gemcitabine
alone or with gemcitabine plus erlotinib [26,27,28,29,30,31].
The behavior of non-target lesions also was concordant. In the
highest ascorbate dose group, non-target lesions were either
improved or stable, and 7 of 9 patients who had pre and post
treatment CT scan evaluations had stable or improved non target
lesions. However, since 3 additional patients died from rapid
progression of the disease the overall result would suggest that 7 of
12 patients had stable disease. The data are consistent with
observed synergy between gemcitabine and pharmacologic
ascorbate in cell and animal experiments [20].
It is noted that RECIST 1.0 criteria for stable disease are
inclusive of a 19% increase in target lesions [24]. Other studies of
gemcitabine efficacy in pancreatic cancer that categorize disease as
stable do not provide details concerning target lesion increases
under 20%, meaning that subjects with target lesion size increases
up to 19% are still considered stable disease. Therefore, the
importance of our finding of target size decrease in 8 of 9 subjects
may be underestimated. RECIST 1.0 criteria for partial response
require that there be at least a 30% decrease in target lesions
without definitive increase in non-target lesions. In addition, many
efficacy studies of gemcitabine based therapies for pancreatic
cancer patients include both metastatic and locally advanced
patients [26]. Our study included only metastatic patients.
There were other potential issues with properly capturing the
efficacy signal of ascorbic acid plus gemcitabine and erlotinib in
this trial design. Ascorbic acid may act differently than classic
cytotoxic chemotherapy. In particular, unlike many cancer
therapies, ascorbate does not appear to have toxicity on rapidly
dividing normal cells such as those in intestine cells, hair follicle
cells, and bone marrow. Because of the absence of apparent tissue
toxicity, effects of ascorbic acid treatment on human tumors might
be expected to be more gradual, and as a corollary to require
longer treatment. This possibility is consistent with observations
from case reports of patients who received intravenous ascorbic
acid as treatment for several types of cancers [20,32,33].
Given the possibility that longer ascorbic acid treatment is
necessary to see disease improvement by RECIST 1.0 criteria, and
the somewhat encouraging findings in the nine subjects in this
trial, studying a longer treatment period at the 100 gram dosage
seems warranted. Although our determination of progression free
survival and overall survival were comparable to values previously
reported for gemcitabine/erlotinib therapy alone [34], the data
are limited by the short treatment duration with ascorbate. Our
primary goal was to evaluate safety of the combination treatment
and provide a preliminary assessment of treatment effect. Because
ascorbic acid appears to be safe with concomitant gemcitabine and
erlotinib, a next reasonable step would be a phase II study with
patients randomized to ascorbic acid plus gemcitabine/erlotinib
versus gemcitabine/erlotinib alone for a longer treatment duration
and to assess for progression free and overall survival.
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Table 3. Response to ascorbic acid plus gemcitabine based on CT findings in patients with scans pre and post the 8 week ascorbic
acid treatment cycle plus gemcitabine/erlotinib (these data only include patients that completed both pre and post-treatment CT
imaging and not the additional five patients who terminated participation early).
Patient (Dose) Pancreatic Mass Pancreatic Mass % Change Non-Target RECIST Criteria
Pre (mm) Post (mm) Primary Mass Lesions Response
001 (50 g) 31618 18616 242% Stable SD
002 (50 g) 32620 28622 213% Progressed PD
004 (50 g) 43639 33639 223% Stable SD
005 (75 g) 43619 38621 212% Stable SD
006 (75 g) 92642 82636 211% Stable SD
008 (75 g) 41638 41638 0% Progressed PD
010 (100 g) 59638 48637 219% Stable SD
012 (100 g) 49649 44642 210% Improved SD
014 (100 g) 42622 36617 214% Improved SD
SD=Stable Disease.
PD=Progressive Disease.
doi:10.1371/journal.pone.0029794.t003
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